Oxidative stress plays an important role in skeletal muscle atrophy. Doxorubicin, a conventional chemotherapeutic agent prescribed for cancer, causes skeletal muscle atrophy and adversely affects mobility and strength. Since doxorubicin-induced muscle atrophy is primarily attributable to oxidative stress, its effects could be mitigated by antioxidant-focused therapies; however, these protective therapeutic targets remain ambiguous. This study aimed at demonstrating that doxorubicin triggered severe muscle atrophy via upregulation of oxidative stress (4-Hydroxynonenal and Malondialdehyde) and atrogenes (Atrogin-1/MAFbx and Muscle RING Finger-1) in association with decreased expression of the antioxidant enzyme, extracellular superoxide dismutase (EcSOD), in cultured C2C12 myotubes and mouse skeletal muscle. EcSOD recombinant protein supplementation elevated EcSOD levels on the cellular membrane of cultured myotubes, consequently inhibiting doxorubicin-induced oxidative stress and myotube atrophy. Furthermore, doxorubicin treatment reduced interleukin-1β (IL-1β) mRNA expression in cultured myotubes and skeletal muscle, while transient IL-1β treatment increased EcSOD protein expression on the myotube membrane. Notably, transient IL-1β treatment of cultured myotubes and local administration in mouse skeletal muscle attenuated doxorubicin-induced muscle atrophy, which is associated with increased EcSOD expression. Collectively, these findings reveal that the regulation of skeletal muscle EcSOD via maintenance of IL-1β signaling is a potential therapeutic approach against doxorubicin-and oxidative stress-mediated muscle atrophy. This study was supported by Grant-in-Aid for Scientific Research (B) (15H03080, 18H03153, 21H03326), Grant-in-Aid for Exploratory Research (20K21766), Suzuken Memorial Foundation, Toyoaki Scholarship Foundation, The Nakatomi Foundation, and The Uehara Memorial Foundation (to M.O.). This research was also supported by Grant-in-Aid for JSPS Fellows (20J15551), Grant-in-Aid for Early-Career Scientists (22K17733), Suzuken Memorial Foundation, The Nakatomi Foundation, and The Uehara Memorial Foundation (to M.Y.). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.
Read full abstract